10.11.07
Akorn, Inc. has signed an exclusive licensing, development and supply agreement with Sofgen Pharmaceuticals for the development of an ANDA oral drug product for women's healthcare. Financial terms of the agreement were not disclosed.
Sofgen will be responsible for development and manufacturing of the drug and Akorn will be responsible for the regulatory submission, marketing and distribution in the U.S. and PR. The two companies are expected to begin a Bioequivalence study this October with a projected launch date in late 2009.
Arthur S. Przybyl, Akorn's president and chief executive officer stated, "On September 7, 2007 we previously announced an ANDA filing in collaboration with Sofgen. Building upon that success, we look forward to working together again. This soft gel oral drug product will be the second addition to our pipeline in women's healthcare and potentially a significant revenue contributor for both companies."
Sofgen will be responsible for development and manufacturing of the drug and Akorn will be responsible for the regulatory submission, marketing and distribution in the U.S. and PR. The two companies are expected to begin a Bioequivalence study this October with a projected launch date in late 2009.
Arthur S. Przybyl, Akorn's president and chief executive officer stated, "On September 7, 2007 we previously announced an ANDA filing in collaboration with Sofgen. Building upon that success, we look forward to working together again. This soft gel oral drug product will be the second addition to our pipeline in women's healthcare and potentially a significant revenue contributor for both companies."